| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Diuretic strategies in patients with acute decompensated heart failure.
|
N Engl J Med
|
2011
|
11.99
|
|
2
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
N Engl J Med
|
2008
|
11.61
|
|
3
|
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
N Engl J Med
|
2003
|
10.57
|
|
4
|
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
|
N Engl J Med
|
2004
|
9.13
|
|
5
|
Outcomes of anatomical versus functional testing for coronary artery disease.
|
N Engl J Med
|
2015
|
8.70
|
|
6
|
Ultrafiltration in decompensated heart failure with cardiorenal syndrome.
|
N Engl J Med
|
2012
|
8.28
|
|
7
|
Coronary bypass surgery with or without surgical ventricular reconstruction.
|
N Engl J Med
|
2009
|
7.71
|
|
8
|
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
|
Lancet
|
2012
|
6.69
|
|
9
|
Myocardial viability and survival in ischemic left ventricular dysfunction.
|
N Engl J Med
|
2011
|
6.65
|
|
10
|
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
|
JAMA
|
2013
|
4.85
|
|
11
|
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.
|
N Engl J Med
|
2015
|
4.39
|
|
12
|
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.
|
JAMA
|
2013
|
3.48
|
|
13
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
Lancet
|
2010
|
3.16
|
|
14
|
Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction.
|
J Am Coll Cardiol
|
2013
|
3.15
|
|
15
|
Cardiovascular events during differing hypertension therapies in patients with diabetes.
|
J Am Coll Cardiol
|
2010
|
2.43
|
|
16
|
STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment.
|
J Am Coll Cardiol
|
2010
|
2.39
|
|
17
|
Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction.
|
J Am Coll Cardiol
|
2010
|
2.29
|
|
18
|
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
|
JACC Cardiovasc Imaging
|
2008
|
2.24
|
|
19
|
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
|
Hypertension
|
2007
|
2.22
|
|
20
|
Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction.
|
J Thorac Cardiovasc Surg
|
2012
|
2.10
|
|
21
|
Navigating the crossroads of coronary artery disease and heart failure.
|
Circulation
|
2006
|
2.06
|
|
22
|
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
|
Circulation
|
2010
|
2.00
|
|
23
|
LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR.
|
JACC Cardiovasc Imaging
|
2011
|
1.96
|
|
24
|
Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial.
|
Circulation
|
2012
|
1.91
|
|
25
|
Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults.
|
J Am Soc Echocardiogr
|
2012
|
1.67
|
|
26
|
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
|
Am Heart J
|
2011
|
1.65
|
|
27
|
Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank).
|
Am J Cardiol
|
2002
|
1.60
|
|
28
|
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
|
Circulation
|
2005
|
1.59
|
|
29
|
Utility of a simple algorithm to grade diastolic dysfunction and predict outcome after coronary artery bypass graft surgery.
|
Ann Thorac Surg
|
2011
|
1.58
|
|
30
|
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction.
|
Eur J Heart Fail
|
2010
|
1.55
|
|
31
|
Outcomes by race and etiology of patients with left ventricular systolic dysfunction.
|
Am J Cardiol
|
2005
|
1.53
|
|
32
|
Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance.
|
Am J Cardiol
|
2006
|
1.48
|
|
33
|
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT).
|
Eur Heart J
|
2009
|
1.48
|
|
34
|
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
|
J Am Coll Cardiol
|
2008
|
1.48
|
|
35
|
Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF).
|
J Card Fail
|
2008
|
1.44
|
|
36
|
Prognostic usefulness of left ventricular thrombus by echocardiography in dilated cardiomyopathy in predicting stroke, transient ischemic attack, and death.
|
Am J Cardiol
|
2004
|
1.44
|
|
37
|
To STICH or not to STICH: we know the answer, but do we understand the question?
|
J Thorac Cardiovasc Surg
|
2005
|
1.44
|
|
38
|
Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction.
|
J Am Coll Cardiol
|
2008
|
1.41
|
|
39
|
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
|
Heart Rhythm
|
2006
|
1.41
|
|
40
|
Clinical characteristics and referral pattern of patients with left ventricular dysfunction and significant coronary artery disease undergoing radionuclide imaging.
|
J Nucl Cardiol
|
2004
|
1.40
|
|
41
|
Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials.
|
Cardiology
|
2015
|
1.38
|
|
42
|
Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya.
|
PLoS One
|
2011
|
1.38
|
|
43
|
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease.
|
J Am Coll Cardiol
|
2013
|
1.34
|
|
44
|
Repeatability and reproducibility of phase analysis of gated single-photon emission computed tomography myocardial perfusion imaging used to quantify cardiac dyssynchrony.
|
Nucl Med Commun
|
2008
|
1.33
|
|
45
|
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Circulation
|
2004
|
1.33
|
|
46
|
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy.
|
Eur Heart J
|
2012
|
1.33
|
|
47
|
Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction.
|
J Am Coll Cardiol
|
2013
|
1.31
|
|
48
|
Mobile health for non-communicable diseases in Sub-Saharan Africa: a systematic review of the literature and strategic framework for research.
|
Global Health
|
2014
|
1.25
|
|
49
|
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
|
Circulation
|
2010
|
1.24
|
|
50
|
Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease.
|
Psychosom Med
|
2013
|
1.24
|
|
51
|
Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: an academic model for countering the epidemic.
|
Am Heart J
|
2011
|
1.22
|
|
52
|
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
|
Eur J Heart Fail
|
2006
|
1.22
|
|
53
|
HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research.
|
J Acquir Immune Defic Syndr
|
2014
|
1.22
|
|
54
|
Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction.
|
JACC Cardiovasc Imaging
|
2013
|
1.20
|
|
55
|
Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of <or=35%.
|
Am J Cardiol
|
2007
|
1.17
|
|
56
|
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
|
Am J Med
|
2013
|
1.17
|
|
57
|
Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study.
|
Eur Heart J
|
2008
|
1.16
|
|
58
|
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
|
Eur Heart J
|
2008
|
1.15
|
|
59
|
Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging.
|
J Nucl Cardiol
|
2010
|
1.14
|
|
60
|
Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials.
|
J Am Soc Echocardiogr
|
2012
|
1.13
|
|
61
|
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
Eur J Heart Fail
|
2009
|
1.13
|
|
62
|
The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study.
|
J Am Coll Cardiol
|
2007
|
1.13
|
|
63
|
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function.
|
Eur Heart J
|
2007
|
1.11
|
|
64
|
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.
|
Am Heart J
|
2006
|
1.10
|
|
65
|
HIV and cardiovascular disease in sub-Saharan Africa: the Sutton Law as applied to global health.
|
J Am Coll Cardiol
|
2013
|
1.09
|
|
66
|
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
|
Blood Press
|
2008
|
1.08
|
|
67
|
Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease.
|
Circ Heart Fail
|
2013
|
1.04
|
|
68
|
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
|
Eur Heart J
|
2009
|
1.03
|
|
69
|
Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis.
|
Am Heart J
|
2003
|
1.03
|
|
70
|
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
|
Eur Heart J
|
2009
|
1.03
|
|
71
|
Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease.
|
Am J Cardiol
|
2009
|
1.01
|
|
72
|
Contemporary performance of surgical ventricular restoration procedures: data from the Society of Thoracic Surgeons' National Cardiac Database.
|
Am Heart J
|
2006
|
1.00
|
|
73
|
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
|
Am Heart J
|
2010
|
0.99
|
|
74
|
The STICH trial: evidence-based conclusions.
|
Eur J Heart Fail
|
2010
|
0.99
|
|
75
|
Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: results from the Duke Databank for Cardiovascular Disease (DDCD).
|
Am Heart J
|
2012
|
0.98
|
|
76
|
Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial.
|
Trials
|
2014
|
0.96
|
|
77
|
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
|
J Am Soc Echocardiogr
|
2006
|
0.96
|
|
78
|
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
|
Am J Hypertens
|
2004
|
0.95
|
|
79
|
Heart failure in sub-Saharan Africa.
|
Curr Cardiol Rev
|
2013
|
0.94
|
|
80
|
Left ventricular assessment in myocardial infarction: the VALIANT registry.
|
Arch Intern Med
|
2005
|
0.92
|
|
81
|
Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction.
|
J Nucl Cardiol
|
2008
|
0.92
|
|
82
|
Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization.
|
Am J Cardiol
|
2004
|
0.90
|
|
83
|
Impact of early surgery on survival of patients with severe mitral regurgitation.
|
Heart
|
2010
|
0.90
|
|
84
|
Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Outcomes Writing Group.
|
Circulation
|
2005
|
0.89
|
|
85
|
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial.
|
Heart
|
2010
|
0.89
|
|
86
|
Waiting to inhale: An exploratory review of conditions that may predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in low- and middle-income countries.
|
Glob Heart
|
2012
|
0.89
|
|
87
|
Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials.
|
Circ Heart Fail
|
2013
|
0.87
|
|
88
|
Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial.
|
Am Heart J
|
2009
|
0.87
|
|
89
|
Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy.
|
Eur Heart J
|
2012
|
0.86
|
|
90
|
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both.
|
Am Heart J
|
2011
|
0.84
|
|
91
|
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.
|
Breast Cancer Res Treat
|
2014
|
0.84
|
|
92
|
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
|
Am Heart J
|
2007
|
0.84
|
|
93
|
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2005
|
0.84
|
|
94
|
Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings.
|
J Nucl Cardiol
|
2007
|
0.84
|
|
95
|
Blood pressure level impacts risk of death among HIV seropositive adults in Kenya: a retrospective analysis of electronic health records.
|
BMC Infect Dis
|
2014
|
0.83
|
|
96
|
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
|
Am Heart J
|
2004
|
0.83
|
|
97
|
Mechanisms of functional mitral regurgitation in ischemic cardiomyopathy determined by transesophageal echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial).
|
Am J Cardiol
|
2013
|
0.83
|
|
98
|
Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study.
|
Am Heart J
|
2004
|
0.83
|
|
99
|
Use of phase analysis of gated SPECT perfusion imaging to quantify dyssynchrony in patients with mild-to-moderate left ventricular dysfunction.
|
J Nucl Cardiol
|
2009
|
0.83
|
|
100
|
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.
|
Circ Heart Fail
|
2013
|
0.83
|
|
101
|
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
Am Heart J
|
2005
|
0.82
|
|
102
|
Evidence for the efficacy of ARBs across the cardiovascular continuum.
|
Curr Med Res Opin
|
2010
|
0.82
|
|
103
|
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
|
Blood Press
|
2011
|
0.82
|
|
104
|
Therapies to prevent heart failure post-myocardial infarction.
|
Curr Heart Fail Rep
|
2005
|
0.81
|
|
105
|
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
|
Hypertension
|
2010
|
0.81
|
|
106
|
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
|
Am J Cardiol
|
2008
|
0.81
|
|
107
|
Left ventricular mechanical dyssynchrony as assessed by phase analysis of ECG-gated SPECT myocardial perfusion imaging.
|
Echocardiography
|
2008
|
0.80
|
|
108
|
Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention.
|
Am J Cardiol
|
2008
|
0.79
|
|
109
|
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
Am Heart J
|
2006
|
0.77
|
|
110
|
Predicting significant coronary artery disease in patients with left ventricular dysfunction.
|
Am Heart J
|
2006
|
0.77
|
|
111
|
Emerging role of myocardial perfusion imaging to evaluate patients for cardiac resynchronization therapy.
|
Am J Cardiol
|
2008
|
0.77
|
|
112
|
A quality improvement framework for equity in cardiovascular care: results of a national collaborative.
|
J Healthc Qual
|
2013
|
0.76
|
|
113
|
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
|
Am J Cardiol
|
2009
|
0.75
|
|
114
|
Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow-up from the STICH trial.
|
Eur J Heart Fail
|
2015
|
0.75
|
|
115
|
Platypnea-Orthodeoxia Syndrome: To Shunt or Not to Shunt, That is the Question.
|
Tex Heart Inst J
|
2016
|
0.75
|
|
116
|
Letter by Bourque et al regarding article, "Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994".
|
Circulation
|
2006
|
0.75
|
|
117
|
Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.
|
J Cardiovasc Pharmacol
|
2015
|
0.75
|
|
118
|
Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?
|
Am Heart J
|
2003
|
0.75
|
|
119
|
Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial.
|
Ann Intern Med
|
2014
|
0.75
|
|
120
|
Getting to a Man's Heart through His Colon.
|
Tex Heart Inst J
|
2016
|
0.75
|
|
121
|
Nitrates in Heart Failure with Preserved Ejection Fraction.
|
N Engl J Med
|
2016
|
0.75
|
|
122
|
Therapy for mental stress-induced myocardial ischemia--reply.
|
JAMA
|
2013
|
0.75
|
|
123
|
Use of valsartan in post-myocardial infarction and heart failure patients.
|
J Renin Angiotensin Aldosterone Syst
|
2006
|
0.75
|
|
124
|
Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention.
|
Circulation
|
2011
|
0.75
|
|
125
|
Temporal Trends in Disease Severity and Predicted Surgical Risk at the Time of Referral for Echocardiography in Patients Diagnosed with Aortic Stenosis.
|
Crit Pathw Cardiol
|
2015
|
0.75
|
|
126
|
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Am Heart J
|
2006
|
0.75
|
|
127
|
Symposium reporter 2003. New therapeutic options in the management of hypertension to heart failure. Orlando, Florida, USA, March 6, 2003.
|
J Am Med Dir Assoc
|
2003
|
0.75
|
|
128
|
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction.
|
Am Heart J
|
2011
|
0.75
|